Testing two immunotherapy drugs before surgery for advanced head and neck cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Lungs & breathing, Mouth & dental clinical trials.
This trial tests whether adding a second immunotherapy drug (CDX-1140) to the standard immunotherapy cemiplimab before surgery is better than cemiplimab alone for people with stage III-IV head and neck cancer that can be removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III or IV head and neck squamous cell cancer (mouth, throat, voice box, or nasal cavity) that can be surgically removed and is accessible for a biopsy.
- If you have oropharyngeal cancer (throat cancer), it must not be linked to HPV (p16-negative).
- You are 18 years or older.
- Your overall health allows you to be up and about (ECOG score 0-2).
- You have not had prior treatment with a PD-1 or PD-L1 inhibitor (like cemiplimab).
- You do not have an active autoimmune disease or history of it in the past 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests how well cemiplimab (an immune treatment) can work when combined with chemotherapy and an additional immunotherapy for certain head and neck cancers. It may help shrink the cancer and improve outcomes, while also checking safety and dosing.
This trial tests whether adding cetuximab to the standard drug pembrolizumab works better for head and neck cancer that has spread or come back after treatment. It is for people whose cancer did not respond to platinum chemotherapy and whose tumors have a certain immune marker (PD-L1).
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
This trial tests whether giving chemotherapy or chemotherapy plus immunotherapy before surgery can improve outcomes for people with advanced head and neck cancer that has come back or not gone away after prior treatment.
This trial compares two immunotherapy drugs (ivonescimab and pembrolizumab) given with standard chemotherapy before and possibly after surgery for advanced head and neck cancer that can be removed. The aim is to see which drug is better at shrinking the tumor and improving outcomes.
This trial tests whether combining two immunotherapy drugs before surgery is better than one alone for advanced head and neck cancer. The goal is to see if the combination can shrink tumors more and improve outcomes.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.